Journal
CARDIOLOGY CLINICS
Volume 33, Issue 2, Pages 309-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.ccl.2015.02.007
Keywords
Hypertriglyceridemia; Atherosclerosis; Cardiovascular disease; Triglycerides
Categories
Ask authors/readers for more resources
Mendelian randomization data strongly suggest that hypertriglyceridemia (HTG) causes atherosclerotic cardiovascular disease (ASCVD), and so triglyceride (TG) level lowering treatment in HTG is now more strongly recommended to address the residual ASCVD risk than has been the case in (generally earlier) published guidelines. Fibrates are the best-established agents for TG level lowering and are generally used as first-line treatment of TG levels greater than 500 mg/dL and prescription omega-3 and niacin are also useful. Statins are the best-established agents for ASCVD prevention, and so are usually used as first-line treatment of TG levels less than 500 mg/dL.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available